Who owns IRulya Therapeutics Inc.?
The parent company, the largest shareholders that report their holdings, the funds that own IRulya Therapeutics Inc. and what its insiders traded, each from the filing that states it.
The short answer
IRulya Therapeutics Inc. is a listed company: its shares trade on Nasdaq, so it is owned by its shareholders.
33 institutional investors that report to the SEC on Form 13F held 20.5% of its shares on Sep 30, 2026.
The largest of them was Janus Henderson Group Ltd. with 15.82%, followed by Ikarian Capital, LLC (0.88%) and Squadron Capital Management LLC (0.83%).
1 mutual fund held 1.2% of the company in their latest reports (the newest of Jun 30, 2026); the largest position was Vanguard Extended Market Index Fund's.
In the last 12 months its insiders reported no purchases and 1 sale worth $0 M on SEC Form 4.
Newest figure: Sep 30, 2026.
Holdings reported on SEC Form 13F for the quarter ended Sep 30, 2026: 33 holders, 20.5% of the shares together.
| # | Holder | Of the shares | Value | Shares | Change in the quarter |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 15.82% | $53 M | 1.7 M | — |
| 2 | Ikarian Capital, LLC | 0.88% | $3 M | 95,652 | +32.4% |
| 3 | Squadron Capital Management LLC | 0.83% | $3 M | 90,000 | +122.9% |
| 4 | Millennium Management LLC | 0.67% | $2 M | 72,254 | +2.1% |
| 5 | Balyasny Asset Management L.P. | 0.65% | $2 M | 69,970 | 0.0% |
| 6 | Acuta Capital Partners, LLC | 0.49% | $2 M | 52,918 | new |
| 7 | Birchview Capital, LP | 0.37% | $1 M | 40,601 | new |
| 8 | Boothbay Fund Management, LLC | 0.20% | $1 M | 21,291 | +53.0% |
| 9 | Jane Street Group, LLC | 0.19% | $1 M | 20,156 | +59.4% |
| 10 | Seven Fleet Capital Management LP | 0.11% | $0 M | 11,989 | new |
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Filings read up to Nov 17, 2026; the quarter is still being filed (99% of last quarter's holders so far). People who hold shares in their own name, such as founders, are not in 13F reports
How ownership moved#
Institutions held 20.5% of IRulya Therapeutics Inc. at Sep 30, 2026, down 11.94 points from Jun 30, 2026; 6 more institutions.
| Quarter end | Institutions | Share of the company | Shares bought | Shares sold | Positions opened | Positions closed |
|---|---|---|---|---|---|---|
| Sep 30, 2026(still being filed) | 33 | 20.5% | 207,753 | 10,857 | 9 | 5 |
| Jun 30, 2026 | 27 | 32.5% | 330,062 | 0 | 27 | — |
Bought most, quarter to Sep 30, 2026
- Squadron Capital Management LLC+49,625
- Ikarian Capital, LLC+23,401
- Jane Street Group, LLC+7,514
- Boothbay Fund Management, LLC+7,380
- Vanguard Fiduciary Trust Co+1,758
- Millennium Management LLC+1,475
- Jpmorgan Chase & Co+790
- Wells Fargo & Company/mn+304
Sold most
- UBS Group AG−4,726
- Morgan Stanley−3,290
- Vanguard Capital Management LLC−2,828
- BlackRock, Inc.−13
New positions (shares held)
- Acuta Capital Partners, LLC52,918
- Birchview Capital, LP40,601
- Seven Fleet Capital Management LP11,989
- Geode Capital Management, LLC9,741
- Group One Trading LLC234
- BNP Paribas Financial Markets9
- Osaic Holdings, Inc.2
- FMR LLC1
Insiders' open-market purchases (up) and sales (down), by quarter
Source: SEC Form 13F data sets and Forms 4 and 5. Institutions report three months after each quarter; a quarter's purchases and sales add up each institution's change since its report for the quarter before. Insiders' trades count open-market purchases and sales only, in the company's reporting currency. 1 mutual funds and ETFs hold IRulya Therapeutics Inc. in their latest reports: 1 new, 0 adding, 0 cutting.
1 funds held 1.2% of the company in their latest reports. Fund holdings are part of what their managers report on Form 13F, so do not add the two.
| Fund | Manager | Country | Of the company | Value | Report of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | The Vanguard Group, Inc. | 🇺🇸 | 1.18% | $0 M | Jun 30, 2026 |
Source: Fund portfolios filed with regulators (SEC Form N-PORT and others) · as of Jun 30, 2026
- Purchases
- 0
- Sales
- 1
- Bought
- $0 M
- Sold
- $0 M
Questions and answers#
Who owns IRulya Therapeutics Inc.?
IRulya Therapeutics Inc. is a listed company: its shares trade on Nasdaq, so it is owned by its shareholders. 33 institutional investors that report to the SEC on Form 13F held 20.5% of its shares on Sep 30, 2026. The largest of them was Janus Henderson Group Ltd. with 15.82%, followed by Ikarian Capital, LLC (0.88%) and Squadron Capital Management LLC (0.83%).
Who is the largest shareholder of IRulya Therapeutics Inc.?
Among investors that file SEC Form 13F, Janus Henderson Group Ltd. was the largest on Sep 30, 2026, with 15.82% of the shares. Founders, executives and other people who hold shares in their own name report them on SEC Forms 3, 4 and 5 and in the proxy statement, not on Form 13F, so they are not in this ranking.
How much of IRulya Therapeutics Inc. do institutional investors own?
33 institutional investors that report to the SEC on Form 13F held 20.5% of its shares on Sep 30, 2026.
Which mutual funds own IRulya Therapeutics Inc.?
1 mutual fund held 1.2% of the company in their latest reports (the newest of Jun 30, 2026); the largest position was Vanguard Extended Market Index Fund's. Funds' holdings are part of what their managers report on Form 13F, so the two shares overlap.
Sources#
Every figure on this page comes from these, with the date shown next to it.
- SEC Form 13F holdings reports
- Fund portfolios filed with regulators (SEC Form N-PORT, Brazil CVM, Sweden Finansinspektionen, Indian fund houses)
- SEC Forms 3, 4 and 5 (insider transactions)
More about IRulya Therapeutics Inc.#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M